Aptevo Reports 21% of Frontline AML Patients Advanced to Stem Cell Transplant
Aptevo said patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplant after mipletamig combination therapy. The transplant rate compares favorably with historical standard-of-care experience.